For over three decades, UCSF has had a Graduate Program in Pharmaceutical Chemistry (PC). This widely recognized and highly successful program has supplied a legion of outstanding scientists to the academic and industrial research community. For over two decades the program has been supported by the NIH training grant in Pharmaceutical Chemistry and Biopharmaceutical Sciences. The current application is a competitive renewal of this training grant. The application has been re-titled to Pharmaceutical Sciences and Pharmacogenomics (PSPG) to reflect the evolution of the training program in response to exciting scientific developments in the area of genomics that have far-reaching implications to the pharmaceutical and pharmacological sciences. The PSPG Graduate Program is a cross-disciplinary program that represents the merger at UCSF of scientists working in pharmaceutical sciences and contemporary genetics. This program broadly encompasses the areas of molecular pharmacology related to drug action, drug transport, drug metabolism and drug/gene delivery. The Program also includes the areas of kinetic/dynamic modeling, pharmacogenomics and bioinformatics applied to pharmacogenomics. The program offers in-depth training in these areas through a core curriculum that also encourages breadth of knowledge about these fields. In the past integrative approach has resulted in Ph.D. graduates who have the interdisciplinary insights and quantitative scientific tools that are characteristic of excellent scientists. Consequently our graduates are in high demand in academia, industry and government. With the identification and mapping of nearly 100,000 genes through the Human Genome Project, it is anticipated that there will be a major impact on diagnosis and treatment of human disease. There is enormous excitement in the pharmaceutical sciences and in human genetics, as people in each of these historically separate areas realize that understanding genetic contributions to drug response is an exciting frontier for both groups. Our program is one of the very few in the World with faculty expertise that spans these fields hence we believe the training program is ideally situated to provide the future scientific leaders in these scientific areas.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Institutional National Research Service Award (T32)
Project #
5T32GM007175-28
Application #
6771701
Study Section
National Institute of General Medical Sciences Initial Review Group (BRT)
Program Officer
Preusch, Peter C
Project Start
1982-07-01
Project End
2007-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
28
Fiscal Year
2004
Total Cost
$232,125
Indirect Cost
Name
University of California San Francisco
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Hallenbeck, Kenneth K; Davies, Julia L; Merron, Connie et al. (2018) A Liquid Chromatography/Mass Spectrometry Method for Screening Disulfide Tethering Fragments. SLAS Discov 23:183-192
Carr, Jessie S; Bonham, Luke W; Morgans, Alicia K et al. (2018) Genetic Variation in the Androgen Receptor and Measures of Plasma Testosterone Levels Suggest Androgen Dysfunction in Alzheimer's Disease. Front Neurosci 12:529
Liang, Xiaomin; Yee, Sook Wah; Chien, Huan-Chieh et al. (2018) Organic cation transporter 1 (OCT1) modulates multiple cardiometabolic traits through effects on hepatic thiamine content. PLoS Biol 16:e2002907
Razavi, Pedram; Chang, Matthew T; Xu, Guotai et al. (2018) The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell 34:427-438.e6
Chung, Shan; Lin, Yuwen Linda; Nguyen, Van et al. (2018) Development of a label-free FcRn-mediated transcytosis assay for in vitro characterization of FcRn interactions with therapeutic antibodies and Fc-fusion proteins. J Immunol Methods 462:101-105
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Ryu, Jae Kyu; Rafalski, Victoria A; Meyer-Franke, Anke et al. (2018) Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegeneration. Nat Immunol 19:1212-1223
Imperial, Marjorie Z; Nahid, Payam; Phillips, Patrick P J et al. (2018) A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nat Med 24:1708-1715
Bielski, Craig M; Donoghue, Mark T A; Gadiya, Mayur et al. (2018) Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer Cell 34:852-862.e4
Soumerai, Tara E; Donoghue, Mark T A; Bandlamudi, Chaitanya et al. (2018) Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer. Clin Cancer Res 24:5939-5947

Showing the most recent 10 out of 193 publications